Treatment of dyslipidemia in chronic kidney disease: Effectiveness and safety of statins

doi:10.5527/wjn.v1.i6.184

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 1, Issue 6

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (4462)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-3) series, Tables (1-3) series.

Item

Count

PDF

493

HTML

3593

Figures (1-3)

252

Tables (1-3)

124

Sum=4462

Dec 6, 2012 (publication date) through Apr 26, 2024

Times Cited of This Article

Times Cited (23)

Journal Information of This Article

Publication Name

World Journal of Nephrology

ISSN

2220-6124

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Minireview

World J Nephrol. Dec 6, 2012; 1(6): 184-194
Published online Dec 6, 2012. doi: 10.5527/wjn.v1.i6.184

Full Size Figure Download Figure

Figure 1 Diagram of the lecithin: cholesterol acyltransferase reaction[18]. Cholesterol acyltransferase (LCAT) cleaves the fatty acid (R2) from the sn-2 position of phosphatidylcholine and then transesterifies it to the A-ring of cholesterol, producing lysophosphatidylcholine and cholesteryl ester. CE: Cholesteryl ester; CETP: Cholesteryl ester transfer protein; HDL: High-density lipoprotein; LDL: Low-density lipoprotein; TG: Triglyceride; SR-BI: Scavenger receptor class B type I.

Citation: Scarpioni R, Ricardi M, Albertazzi V, Melfa L. Treatment of dyslipidemia in chronic kidney disease: Effectiveness and safety of statins. World J Nephrol 2012; 1(6): 184-194
URL: https://www.wjgnet.com/2220-6124/full/v1/i6/184.htm
DOI: https://dx.doi.org/10.5527/wjn.v1.i6.184